Tirzepatide Pen (1 month)

Tirzepatide is a dual GIP and GLP-1 receptor agonist, meaning it mimics two natural hormones:

• GIP (glucose-dependent insulinotropic polypeptide)

• GLP-1 (glucagon-like peptide-1)

Weight Loss Benefits

In clinical studies, patients lost an average of 15–22.5% of their body weight, depending on the dose. That’s more than many other GLP-1 medications like Semaglutide (Ozempic, Wegovy).

How It’s Taken

• Once-weekly subcutaneous injection

• Available in pre-filled pens with varying doses (e.g., 2.5mg, 5mg, up to 15mg)

• Dosing is typically titrated (increased gradually) to reduce side effects

Possible Side Effects

Most are gastrointestinal and mild to moderate:

• Nausea

• Diarrhea or constipation

• Decreased appetite

• Fatigue

• Injection site reactions

Contraindications / Warnings

• Personal or family history of medullary thyroid carcinoma (MTC)

• MEN2 syndrome

• Pregnant or breastfeeding women should not use it